| Acne Vulgaris

Absorica vs Clindagel

Side-by-side clinical, coverage, and cost comparison for acne vulgaris.
Deep comparison between: Absorica Ld vs Clindagel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsClindagel has a higher rate of injection site reactions vs Absorica Ld based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Clindagel but not Absorica Ld, including UnitedHealthcare
Sign up to reveal the full AI analysis
Absorica Ld
Clindagel
At A Glance
Oral
Twice daily
Retinoid
Topical
Once daily
Topical antibiotic (lincosamide)
Indications
  • Acne Vulgaris
  • Acne Vulgaris
Dosing
Acne Vulgaris ABSORICA: 0.5 to 1 mg/kg/day in two divided doses for 15 to 20 weeks (up to 2 mg/kg/day for severe disease with scarring or trunk involvement); ABSORICA LD: 0.4 to 0.8 mg/kg/day in two divided doses for 15 to 20 weeks (up to 1.6 mg/kg/day for severe disease).
Acne Vulgaris Apply a thin film once daily to the skin where acne lesions appear, covering the entire affected area lightly.
Contraindications
  • Pregnancy
  • Hypersensitivity to isotretinoin, Vitamin A (given chemical similarity), or any component of the product
  • History of hypersensitivity to preparations containing clindamycin or lincomycin
  • History of regional enteritis or ulcerative colitis
  • History of antibiotic-associated colitis
Adverse Reactions
Most common Cheilitis, hypertriglyceridemia, dry skin, dry lips, fatigue, headache, epistaxis, arthralgia, back pain, musculoskeletal pain
Serious Embryo-fetal toxicity, psychiatric disorders (including suicidal ideation, depression, psychosis), intracranial hypertension, serious skin reactions, pancreatitis, hepatotoxicity, inflammatory bowel disease, musculoskeletal abnormalities, hearing impairment, hypersensitivity reactions
Most common (>=1%) Pruritus, peeling
Serious Severe colitis, pseudomembranous colitis, diarrhea, bloody diarrhea, abdominal pain, gram-negative folliculitis
Pharmacology
Isotretinoin is a retinoid that inhibits sebaceous gland function and keratinization; clinical improvement in nodular acne is associated with a reduction in sebum secretion, reflecting reduced sebaceous gland size and inhibition of sebaceous gland differentiation.
Clindamycin phosphate is a semi-synthetic lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing Propionibacterium acnes growth.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Absorica Ld
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
View full coverage details ›
Clindagel
  • Covered on 5 commercial plans
  • PA (1/12) · Step Therapy (0/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Absorica Ld
  • Covered on 4 commercial plans
  • PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Clindagel
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
View full coverage details ›
Humana
Absorica Ld
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
View full coverage details ›
Clindagel
  • Covered on 0 commercial plans
  • PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Absorica Ld.
No savings programs available for Clindagel.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
Absorica LdView full Absorica Ld profile
ClindagelView full Clindagel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.